This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.
Age range
12 Weeks – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Safety and reactogenicity of Full-strength and Half-strength TSCV
Timeframe: first 30 minutes after parenteral immunization
Safety and reactogenicity of Full-strength and Half-strength TSCV
Timeframe: over 7 days post-vaccination.
Safety and reactogenicity of Full-strength and Half-strength TSCV
Timeframe: through Day 29 of follow-up post-vaccination
Safety and reactogenicity of Full-strength and Half-strength TSCV
Timeframe: Through Day 366 of follow-up post vaccination
Non-inferiority analysis: immunogenicity of Full-strength vs. Half-strength TSCV
Timeframe: Through day 29 post vaccination
Non-inferiority analysis: immunogenicity of Full-strength vs. Half-strength TSCV
Timeframe: Through day 29 post vaccination
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]
Timeframe: over 7 days post-vaccination.
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]
Timeframe: through Day 29 of follow-up after each vaccination.
Safety and reactogenicity after primary dose of TSCV and after booster dose of TSCV or Typbar-TCV™ [At each booster age group (9, 12, or 15-17 mo. of age)]
Timeframe: Until the end of the participant study period - 6 months to 1 year post vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination
Immunogenicity of two-dose regimen of TSCV [At each booster age group (9, 12 or 15-17 months of age)]
Timeframe: At day 29 post booster vaccination